We evaluated the efficacy of NXL104, a novel ␤-lactamase inhibitor, in combination with ceftazidime (CAZ) in two murine infection models (septicemia and thigh infection). We chose two KPC-producing Klebsiella pneumoniae strains (VA-361 and VA-406) showing MICs of CAZ of >256 g/ml. Septicemia was induced by the intraperitoneal injection of KPC-producing K. pneumoniae followed 30 min later by a single subcutaneous treatment with CAZ alone or CAZ-NXL104 in ratios of 2:1, 4:1, 8:1, and 16:1. In this model, the median effective doses for 50% (ED 50 ) of the animals for CAZ alone versus VA-361 and VA-406 were 1,578 and 709 mg/kg of body weight, respectively. When combined with NXL104 at 2:1, 4:1, 8:1, and 16:1 ratios, the CAZ ED 50 s for VA-361 and VA-406 were reduced to 8.1 and 3.5 mg/kg, 15.1 and 3.8 mg/kg, 16.9 and 7.2 mg/kg, and 29.5 and 12.1 mg/kg, respectively. For thigh infection, neutropenia was induced by the intraperitoneal injection of cyclophosphamide at days ؊4 and ؊1 preinfection. Infection was established by the intramuscular injection of KPC-producing K. pneumoniae into the right thigh. Mice were treated 1.5 h postinfection with either CAZ alone or CAZ-NXL104 at constant ratios of 4:1. When thighs were removed at 24 h postinfection, a >2-log CFU reduction was observed for mice treated with CAZ-NXL104 at doses of >128:32 mg/kg. In contrast, CAZ doses of >1,024 mg/kg were unable to reduce the numbers of CFU. Despite resistance to CAZ and possessing a complex ␤-lactamase background, NXL104 combined with CAZ proved to be very effective in murine models of infection due to contemporary highly resistant KPC-producing K. pneumoniae isolates.
The spread of class A KPC carbapenemases among the family Enterobacteriaceae (particularly Klebsiella pneumoniae), Pseudomonas spp., and Acinetobacter baumannii is drawing significant attention due to the important clinical implications that this resistance determinant bears for infected patients (11, 21, 25) . KPC-producing K. pneumoniae isolates are endemic in certain hospitals and are responsible for increasing numbers of outbreaks in many health care facilities located in the United States, Puerto Rico, Israel, Greece, and Germany (10, 17, 27) . Sporadic detection in Central and South America, the Far East, and other European countries has also been reported (1, 9, 17, 18, 20, 23) .
KPC-producing K. pneumoniae isolates demonstrate resistance or reduced susceptibility to most commercially available ␤-lactams and ␤-lactam/␤-lactamase inhibitor combinations as well as many other alternative classes of antimicrobials (e.g., fluoroquinolones and aminoglycosides) (5, 17) . Thus, colistin, tigecycline, and fosfomycin are becoming the "last-line" therapeutic options for infections due to KPC-producing K. pneumoniae isolates. Unfortunately, the clinical use (e.g., dosage and time of treatment) of these antimicrobials is not yet fully defined, and their resistance rates for KPC-producing K. pneumoniae strains are also quickly increasing (7, 11, 15, 23, 28) .
Relatively few novel compounds are in development that promise to be active against Gram-negative multidrug-resistant (MDR) pathogens, such as those producing KPC enzymes (3, 6) . NXL104 (Novexel SA, Romainville, France, and AstraZeneca Pharmaceuticals, Boston, MA) is a new ␤-lactamases inhibitor that is active against class A (e.g., TEM, SHV, and CTX-M types) and class C ␤-lactamases and is currently in clinical trials (http://clinicaltrials.gov) (2, 14, 22) . Recently, Endimiani et al. demonstrated its in vitro activity in combination with standard ␤-lactams against a large collection of KPCproducing K. pneumoniae isolates collected in the Eastern United States (4). In particular, the MICs of the combination of NXL104 at a constant concentration of 4 g/ml with piperacillin, extended-spectrum cephalosporins (e.g., ceftazidime and cefotaxime), and aztreonam were in the susceptible range for all tested strains (overall, MIC 90 values of Յ2 g/ml) (4).
In the present work, we evaluated the in vivo antibacterial efficacy of ceftazidime (CAZ) in combination with NXL104 in a mouse septicemia model and a mouse thigh infection model using two well-characterized KPC-producing K. pneumoniae strains. Our data show that the addition of NXL104 results in a significant restoration of ceftazidime efficacy and the ability to eradicate infections due to KPC-producing K. pneumoniae isolates.
MATERIALS AND METHODS

Clinical isolates.
In vivo experiments were conducted by using two KPCproducing K. pneumoniae isolates (i.e., VA-361 and VA-406) characterized previously (4, 5) . Both strains were collected in the Eastern United States and are clonally related by pulsed-field gel electrophoresis (PFGE) and repetitive extragenic palindromic PCR (rep-PCR) analyses (5) . The molecular and phenotypic profiles of the two KPC-producing K. pneumoniae isolates are shown in Table 1 . K. pneumoniae isolate ATCC 13883 was also used as a control. This ATCC strain has an MIC value of CAZ of 2 g/ml.
Mice. Female 5-to 6-week-old CD-1 mice (Harlan Laboratories, Houston, TX) were used for both acute lethal septicemia and thigh infection models (see below). All studies were carried out according to protocols approved by the Institutional Animal Care and Use Committee (University of North Texas Health Science Center at Fort Worth). During the study, mice were housed in groups of 3 to 5 with free access to food and water in accordance with National Institutes of Health guidelines.
Murine acute lethal septicemia. Mice were infected by the intraperitoneal (i.p.) injection of the KPC-producing K. pneumoniae strain resulting in the death of untreated controls within 24 to 48 h. In particular, a fresh predetermined bacterial inoculum of approximately 3.3 ϫ 10 5 to 3.6 ϫ 10 5 CFU in 5% hog gastric mucin grown overnight was used for both KPC-producing K. pneumoniae isolates. Thirty minutes postinfection, a single subcutaneous dose of ceftazidime (Sigma-Aldrich, St. Louis, MO) with and without NXL104 (see below for dosages) was initiated, and the survival ratio was monitored for 5 days twice a day.
For K. pneumoniae VA-361, 5 mice/dose level for each of the following treatment regimens were tested: CAZ alone (doses of 512, 1,024, and 2,048 mg/kg of body weight) and CAZ plus NXL104 at ratios of 2:1, 4:1, 8:1, and 16:1 (CAZ doses were 4, 8, 16, 32, and 64 mg/kg for each ratio). Tests were performed three times for each dose on separate days. Similarly, for K. pneumoniae VA-406, the following treatment regimens were evaluated: CAZ alone (doses of 256, 512, 1,024, and 2,048 mg/kg) and CAZ plus NXL104 at ratios of 2:1 and 4:1 (CAZ doses of 1, 2, 4, 8, and 16 mg/kg for each ratio) and 8:1 and 16:1 (CAZ doses of 2, 4, 8, 16, and 32 mg/kg for each ratio). Tests were performed three times for each dose on separate days. The median effective dose for 50% (ED 50 ) of animals was determined by a computerized program of Probit analysis for both KPC-producing K. pneumoniae strains and regarding the different dose regimens tested (26) . Survival rates, stratified for different dose regimens, were also obtained.
Neutropenic murine thigh infection. Mice were rendered neutropenic by the i.p. injection of cyclophosphamide (Cytoxan; Baxter Healthcare, Deerfield, IL) with 150 mg/kg at day Ϫ4 and 100 mg/kg at day Ϫ1 preinfection. Infection was induced by the intramuscular (i.m.) injection of 0.1 ml of sterile saline containing 10 6 CFU of the KPC-producing K. pneumoniae isolate into the right thigh of each animal. Mice were treated subcutaneously 1.5 h postinfection with either CAZ alone or CAZ combined with NXL104 at a constant ratio of 4:1. For each dose group, 3 mice were tested, including the untreated control group. In particular, for VA-361, the ranges of concentrations of CAZ-NXL104 tested were 1,024:256 mg/kg to 32:8 mg/kg, whereas for VA-406, the ranges were 1,024:256 mg/kg to 8:2 mg/kg.
At 24 h postinfection, mice were euthanized by CO 2 inhalation, and thighs were aseptically removed for CFU enumerations. In particular, thighs were homogenized (Polytron tissue homogenizer; Kinematica, Luzern, Switzerland) on ice in sterile saline, diluted, and plated onto Trypticase soy agar with charcoal (to prevent the effects of any carryover of compound). Plates were incubated overnight at 37°C prior to counting of CFU (24) . The relationship of dose versus change in CFU/thigh was determined for all doses administered.
RESULTS AND DISCUSSION
Finding new antimicrobial agents or combinations is becoming an important priority to combat the spread of MDR Gramnegative organisms, such as those producing the KPC carbapenemases (19) . Due to their low toxicity and high bactericidal activity, the use of ␤-lactam antibiotics in combination with new and more-active ␤-lactamases inhibitors seems to be an attractive strategy (2) . Several new ␤-lactam/␤-lactamase inhibitor combinations have recently demonstrated in vitro activity against KPC-producing Enterobacteriaceae (3, 4, 16 ). Although very promising, the in vivo activity of those combinations has not yet been fully evaluated.
In the present work, the in vivo antimicrobial activity of an experimental combination of CAZ plus the new ␤-lactamase inhibitor NXL104 was tested at different ratios in two animal models of infection due to KPC-producing K. pneumoniae. In particular, the two isolates tested (i.e., VA-361 and VA-406) were clinical strains representative of the main clone that is spreading in the United States and widely (5) .
Both KPC-producing K. pneumoniae strains were nonsusceptible in vitro to all ␤-lactams and standard ␤-lactam/␤-lactamase inhibitor combinations. However, VA-406 possessed higher MICs (with particular emphasis on carbapenems) than VA-361 (Table 2 ). This phenomenon is frequently observed in the clinic and is due to a combination of a different OmpK background and/or variable expression levels of KPC enzymes (8, 12, 13). Murine acute lethal septicemia. In Table 3 we show the results of the acute lethal septicemia analysis. For VA-361 and VA-406, CAZ alone exhibited ED 50 values of 1,578 and 709 mg/kg, respectively. These elevated ED 50 s were reduced with the coadministration of NXL104 at the ratios tested. The administration of CAZ-NXL104 at a ratio of 4:1 effectively reduced the ED 50 s for VA-361 and VA-406 to 15.1 and 3.8 mg/kg, respectively ( Table 3 ). As shown in Fig. 1A and B, animal survival increased in relation to the ratio of CAZ to NXL104 for both KPC-producing K. pneumoniae isolates tested. In particular, the addition of NXL104 to CAZ remarkably reduced the amount of CAZ required to treat favorably the systemic infection induced in mice.
Neutropenic murine thigh infection. As shown in Table 4 , following the administration of CAZ-NXL104 at a constant ratio of 4:1, VA-361 exhibited CFU reductions with doses of Ն256:64 mg/kg, whereas for VA-406, CFU reductions were achieved at doses of Ն128:32 mg/kg. The static doses were determined to be 216:54 mg/kg for VA-361 and 116:29 mg/kg for VA-406. Dosages of Յ64:16 mg/kg were unable to reduce the CFU count for both KPC-producing K. pneumoniae isolates (Table 4) .
In both murine models, the more resistant KPC-producing K. pneumoniae isolate VA-406 was more susceptible in vivo (i.e., lower ED 50 and higher CFU reduction) to the CAZ-NXL104 treatment than was VA-361. We do not have a clear explanation for this phenomenon. However, we speculate that the two KPC-producing K. pneumoniae strains posses different virulence factors. Based upon these observations, we maintain that the treatment outcome of infections due to KPC-producing K. pneumoniae isolates is influenced by multiple factors and not only the antimicrobial phenotype obtained in the clinical laboratory.
Conclusion. These data show that the addition of NXL104, a potent ␤-lactamase inhibitor, to CAZ results in the restoration of CAZ efficacy in these two mouse models of infection. Our analysis with K. pneumoniae isolates expressing the clinically relevant KPC ␤-lactamase demonstrates that the usefulness of the CAZ-NXL104 combination was maintained even when there was a disruption of the OmpK channels, as VA-406 possessed MICs against the carbapenems that were well above any reasonably achievable serum levels. The latter feature has significant importance, as current microbiology laboratories will identify KPC-producing K. pneumoniae but will be able to report only a limited amount of information about the strains to clinicians (e.g., susceptible or resistant, modified Hodge test positive or negative, and MIC values), as the MIC endpoints are not routinely measured (8) . Lastly, our observations also raise interesting questions regarding the growth characteristics and antibiotic permeability attributes of strains of K. pneumoniae with OmpK changes, as the efficacy of this CAZ-NXL104 com- 
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